Lenalidomide Treatment for Myelodysplastic Syndrome
Author Information
Author(s): Khalafallah Alhossain, Terry Brain
Primary Institution: Launceston General Hospital, Tasmania, Australia
Hypothesis
Different dosing regimens of lenalidomide may improve hematopoiesis in patients with intermediate to high-risk myelodysplastic syndrome.
Conclusion
Twice weekly lenalidomide dosing can lead to sustained hematological responses and improved quality of life in patients with myelodysplastic syndrome.
Supporting Evidence
- Both patients achieved long-term transfusion independence after starting lenalidomide therapy.
- One patient maintained a sustained erythroid response for over 10 months.
- The modified dosing regimen was well tolerated without significant side effects.
Takeaway
This study shows that giving lenalidomide twice a week can help patients with a blood disorder feel better and not need blood transfusions.
Methodology
Two patients with myelodysplastic syndrome were treated with lenalidomide at a dose of 15 mg twice weekly.
Limitations
The study involves only two patients, limiting the generalizability of the findings.
Participant Demographics
Two Caucasian patients, one female aged 75 and one male aged 73.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website